Actavis launches generic Keppra XR in US
This article was originally published in Scrip
Executive Summary
The fourth largest generics company worldwide, Actavis has launched its Levetiracetam Extended-Release Tablets, a generic equivalent of UCB's Keppra XR, in the US following FDA approval on 15 September. The company began shipping the product immediately following approval.